Literature DB >> 26992920

Drug-Induced Mitochondrial Toxicity.

Iain P Hargreaves1,2, Mesfer Al Shahrani3,4,5, Luke Wainwright6, Simon J R Heales3,6,4,7.   

Abstract

The mitochondrial respiratory chain (MRC) and ATP synthase (complex V) play an essential role in cellular energy production by the process of oxidative phosphorylation. In addition to inborn errors of metabolism, as well as secondary causes from disease pathophysiology, an impairment of oxidative phosphorylation can result from drug toxicity. These 'off-target' pharmacological effects can occur from a direct inhibition of MRC enzyme activity, an induction of mitochondrial oxidative stress, an uncoupling of oxidative phosphorylation, an impairment of mitochondrial membrane structure or a disruption in the replication of mitochondrial DNA. The purpose of this review is to focus on the off-target mitochondrial toxicity associated with both commonly used pharmacotherapies and a topical 'weight loss' agent. The mechanisms of drug-induced mitochondrial impairment will be discussed together with putative therapeutic strategies to counteract the adverse effects of the pharmacotherapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26992920     DOI: 10.1007/s40264-016-0417-x

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  144 in total

1.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.

Authors:  M R Owen; E Doran; A P Halestrap
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

2.  Phosphate transport by reconstructed monolayers from cultured mouse kidney cells.

Authors:  Y Kinoshita; M Fukase; T Kubota; T Fujita
Journal:  Endocrinol Jpn       Date:  1987-08

3.  Bezafibrate induced increase in mitochondrial electron transport chain complex IV activity in human astrocytoma cells: Implications for mitochondrial cytopathies and neurodegenerative diseases.

Authors:  Nicola Ioannou; Iain P Hargreaves; George Allen; Kate Duberley; John M Land; Simon J R Heales
Journal:  Biofactors       Date:  2010-09-24       Impact factor: 6.113

Review 4.  Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

Authors:  P T Männistö; S Kaakkola
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

5.  Simvastatin-induced lactic acidosis: a rare adverse reaction?

Authors:  Anil K Goli; Sujatha A Goli; Ryland P Byrd; Thomas M Roy
Journal:  Clin Pharmacol Ther       Date:  2002-10       Impact factor: 6.875

Review 6.  Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions.

Authors:  QiPing Feng; Russell A Wilke; Tesfaye M Baye
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

7.  Glutathione deficiency in patients with mitochondrial disease: implications for pathogenesis and treatment.

Authors:  I P Hargreaves; Y Sheena; J M Land; S J R Heales
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

Review 8.  Clinical perspectives of statin-induced rhabdomyolysis.

Authors:  Kenneth A Antons; Craig D Williams; Steven K Baker; Paul S Phillips
Journal:  Am J Med       Date:  2006-05       Impact factor: 4.965

9.  Mechanisms of phenytoin-induced toxicity in freshly isolated rat hepatocytes and the protective effects of taurine and/or melatonin.

Authors:  Mohammad Ali Eghbal; Shohreh Taziki; Mohammad Reza Sattari
Journal:  J Biochem Mol Toxicol       Date:  2013-12-03       Impact factor: 3.642

Review 10.  Diagnosis and therapy in neuromuscular disorders: diagnosis and new treatments in mitochondrial diseases.

Authors:  S Rahman; M G Hanna
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-09       Impact factor: 10.154

View more
  13 in total

Review 1.  Diet aid or aid to die: an update on 2,4-dinitrophenol (2,4-DNP) use as a weight-loss product.

Authors:  Daniela Sousa; Helena Carmo; Rita Roque Bravo; Félix Carvalho; Maria de Lourdes Bastos; Paula Guedes de Pinho; Diana Dias da Silva
Journal:  Arch Toxicol       Date:  2020-02-20       Impact factor: 5.153

Review 2.  Mitochondrial Dysfunction in Pulmonary Fibrosis.

Authors:  Sunad Rangarajan; Karen Bernard; Victor J Thannickal
Journal:  Ann Am Thorac Soc       Date:  2017-11

3.  Nucleoside reverse transcriptase inhibitor-induced rat oocyte dysfunction and low fertility mediated by autophagy.

Authors:  Li Tang; Shengfu Yang; Huawei Wang; Hai Gu; Xueshan Xia; Yue Feng; Zexing Yang; Shuhua Zhao; Cunmei Su; Zhenfang Su; Kunhua Wang
Journal:  Oncotarget       Date:  2017-12-13

4.  Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers.

Authors:  Sergio Barroso; Constanza Morén; Àlex González-Segura; Neus Riba; Joan A Arnaiz; Marcela Manriquez; Gemina Santana; José L Blanco; María Larousse; Montse Loncà; Elisa de Lazzari; Jaume Llopis; Josep Mallolas; Oscar Miró; Xavier Carné; Jose M Gatell; Glòria Garrabou; Esteban Martínez
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

5.  Mitochondrial Toxicogenomics for Antiretroviral Management: HIV Post-exposure Prophylaxis in Uninfected Patients.

Authors:  Maria Bañó; Constanza Morén; Sergio Barroso; Diana Luz Juárez; Mariona Guitart-Mampel; Ingrid González-Casacuberta; Judith Canto-Santos; Ester Lozano; Agathe León; Enric Pedrol; Òscar Miró; Ester Tobías; Josep Mallolas; Jhon F Rojas; Francesc Cardellach; Esteban Martínez; Gloria Garrabou
Journal:  Front Genet       Date:  2020-05-26       Impact factor: 4.599

6.  Treatment with the direct oral anticoagulants (DOACs) apixaban and rivaroxaban associated with significant worsening of behavioural and psychological symptoms of dementia (BPSD).

Authors:  Kim Maria Frances Porter; Iain Parry Hargreaves; Stephen De Souza; Rebecca Goddard
Journal:  BMJ Case Rep       Date:  2021-03-08

7.  Detoxifying Enzymes at the Cross-Roads of Inflammation, Oxidative Stress, and Drug Hypersensitivity: Role of Glutathione Transferase P1-1 and Aldose Reductase.

Authors:  Francisco J Sánchez-Gómez; Beatriz Díez-Dacal; Elena García-Martín; José A G Agúndez; María A Pajares; Dolores Pérez-Sala
Journal:  Front Pharmacol       Date:  2016-08-04       Impact factor: 5.810

Review 8.  Oxidative Stress: Mechanistic Insights into Inherited Mitochondrial Disorders and Parkinson's Disease.

Authors:  Mesfer Al Shahrani; Simon Heales; Iain Hargreaves; Michael Orford
Journal:  J Clin Med       Date:  2017-10-27       Impact factor: 4.241

9.  Safety of drug use in patients with a primary mitochondrial disease: An international Delphi-based consensus.

Authors:  Maaike C De Vries; David A Brown; Mitchell E Allen; Laurence Bindoff; Gráinne S Gorman; Amel Karaa; Nandaki Keshavan; Costanza Lamperti; Robert McFarland; Yi Shiau Ng; Mar O'Callaghan; Robert D S Pitceathly; Shamima Rahman; Frans G M Russel; Kristin N Varhaug; Tom J J Schirris; Michelangelo Mancuso
Journal:  J Inherit Metab Dis       Date:  2020-02-07       Impact factor: 4.750

10.  S-15176 Difumarate Salt Can Impair Mitochondrial Function through Inhibition of the Respiratory Complex III and Permeabilization of the Inner Mitochondrial Membrane.

Authors:  Natalia V Belosludtseva; Vlada S Starinets; Alena A Semenova; Anastasia D Igoshkina; Mikhail V Dubinin; Konstantin N Belosludtsev
Journal:  Biology (Basel)       Date:  2022-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.